The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CB2 is upregulated in pro-inflammatory microglia, and CB2 stimulation has been shown to mitigate their activation, making CB2 an attractive therapeutic target”
From Novel floxed cannabinoid receptor 2 mouse line combines knockout capability with dual fluorescent reporters (2025) · cites this paper as Chung et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Liberatore, G. T., Jackson-Lewis, V., Vukosavic, S., Mandir, A. S., Vila, M., McAuliffe, W. G., Dawson, V. L., Dawson, T. M., & Przedborski, S. (1999) · Nature Medicine · doi:10.1038/70978 · Cited by 1,046
Blood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Neuroinflammation in Parkinson's disease
Hirsch, E. C., Vyas, S., & Hunot, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70065-7 · Cited by 657
Peripheral cytokines profile in parkinson’s disease
Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547
Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy
Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B. (2007) · Cell Transplantation · doi:10.3727/000000007783464731 · Cited by 339
Research works printed but not linked: 40
- Savitt JM, Dawson VL, Dawson TM . Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006; 116: 1744–1754. · DOI · Paper page
- Appel SH . CD4+ T cells mediate cytotoxicity in neurodegenerative diseases. J Clin Invest 2009; 119: 13–15.
- Chung YC, Ko HW, Bok E, Park ES, Huh SH, Nam JH et al. The role of neuroinflammation on the pathogenesis of Parkinson’s disease. BMB Rep 2010; 43: 225–232. · DOI
- Hwang O . Role of oxidative stress in Parkinson’s disease. Exp Neurobiol 2013; 22: 11–17. · DOI · Paper page
- Weiss N, Miller F, Cazaubon S, Couraud PO . The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 2009; 1788: 842–857. · DOI · Paper page
- Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson’s disease in mice. J Neurosci 2005; 25: 6594–6600. · DOI · Paper page
- Chung YC, Kim SR, Jin BK . Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson’s disease. J Immunol 2010; 185: 1230–1237. · DOI · Paper page
- Huh SH, Chung YC, Piao Y, Jin MY, Son HJ, Yoon NS et al. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson’s disease. J Immunol 2011; 187: 960–969. · DOI
- Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994; 180: 147–150. · DOI · Paper page
- Nagatsu T, Sawada M . Biochemistry of postmortem brains in Parkinson’s disease: historical overview and future prospects. J Neural Transm Suppl 2007; 72: 113–120. · DOI · Paper page
- Kawamoto Y, Ito H, Ayaki T, Takahashi R . Immunohistochemical localization of apoptosome-related proteins in Lewy bodies in Parkinson’s disease and dementia with Lewy bodies. Brain Res 2014; 1571: 39–48. · DOI
- Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 1994; 372: 686–691. · DOI · Paper page
- Fernandez-Ruiz J, Romero J, Velasco G, Tolon RM, Ramos JA, Guzman M . Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007; 28: 39–45. · DOI · Paper page
- Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, Brusco A et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071: 10–23. · DOI · Paper page
- Onaivi ES . Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006; 54: 231–246. · DOI · Paper page
- Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003; 23: 1398–1405. · DOI · Paper page
- Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A . Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 2003; 41: 161–168. · DOI · Paper page
- Martin-Moreno AM, Reigada D, Ramirez BG, Mechoulam R, Innamorato N, Cuadrado A et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol 2011; 79: 964–973. · DOI · Paper page
- Ramirez BG, Blazquez C, Gomez del Pulgar T, Guzman M, de Ceballos ML . Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J Neurosci 2005; 25: 1904–1913. · DOI · Paper page
- Ortega-Gutierrez S, Molina-Holgado E, Guaza C . Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. Glia 2005; 52: 163–168. · DOI
- Tanikawa T, Kurohane K, Imai Y . Regulatory effect of cannabinoid receptor agonist on chemokine-induced lymphocyte chemotaxis. Biol Pharm Bull 2011; 34: 1090–1093. · DOI
- Fernandez-Lopez D, Faustino J, Derugin N, Wendland M, Lizasoain I, Moro MA et al. Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke. Neuroscience 2012; 207: 307–315. · DOI
- Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z et al. Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 2010; 24: 788–798. · DOI
- Amenta PS, Jallo JI, Tuma RF, Elliott MB . A cannabinoid type 2 receptor agonist attenuates blood-brain barrier damage and neurodegeneration in a murine model of traumatic brain injury. J Neurosci Res 2012; 90: 2293–2305. · DOI
- Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson’s disease patients. Ann Neurol 2005; 57: 777–779. · DOI · Paper page
- Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernandez E et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci 2009; 29: 2177–2186. · DOI · Paper page
- Chung YC, Bok E, Huh SH, Park JY, Yoon SH, Kim SR et al. Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. J Immunol 2011; 187: 6508–6517. · DOI
- Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011; 60: 963–974. · DOI
- Chao YX, He BP, Tay SS . Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson’s disease. J Neuroimmunol 2009; 216: 39–50. · DOI
- Perry VH . Innate inflammation in Parkinson’s disease. Cold Spring Harb Perspect Med 2012; 2: a009373. · DOI
- Shimoji M, Pagan F, Healton EB, Mocchetti I . CXCR4 and CXCL12 expression is increased in the nigro-striatal system of Parkinson's disease. Neurotox Res 2009; 16: 318–328. · DOI
- Panaro MA, Cianciulli A . Current opinions and perspectives on the role of immune system in the pathogenesis of Parkinson’s disease. Curr Pharm Des 2012; 18: 200–208. · DOI
- Depboylu C, Stricker S, Ghobril JP, Oertel WH, Priller J, Hoglinger GU . Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Exp Neurol 2012; 238: 183–191. · DOI
- Episcopo FL, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B . Reactive astrocytes are key players in nigrostriatal dopaminergic neurorepair in the MPTP mouse model of Parkinson's disease: focus on endogenous neurorestoration. Curr Aging Sci 2013; 6: 45–55. · DOI
- Rappold PM, Tieu K . Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics 2010; 7: 413–423. · DOI · Paper page
- Oki C, Watanabe Y, Yokoyama H, Shimoda T, Kato H, Araki T . Delayed treatment with arundic acid reduces the MPTP-induced neurotoxicity in mice. Cell Mol Neurobiol 2008; 28: 417–430. · DOI
- Bolin LM, Strycharska-Orczyk I, Murray R, Langston JW, Di Monte D . Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J Neurochem 2002; 83: 167–175. · DOI
- Hampton MB, Kettle AJ, Winterbourn CC . Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92: 3007–3017. · DOI · Paper page
- Arnhold J, Flemmig J . Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys 2010; 500: 92–106. · DOI · Paper page
- Rite I, Machado A, Cano J, Venero JL . Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007; 101: 1567–1582. · DOI · Paper page
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
“JWH133 also protects against BBB disruption and peripheral immune cell infiltration.(255) These findings suggest that CB2 receptor agonists may serve as potential therapeutic targets for PD.”
BackgroundCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970
Michinaga, S., & Koyama, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030571 · Cited by 263
Chiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“Moreover, CB2 protects neurons from oxidative stress-induced dopaminergic neurodegeneration in several experimental models of PD (Chung et al., 2016; Javed et al., 2016), suggesting that selectively targeting this receptor could be indicated for novel clinical approaches.”
Laloli, K. J., Rentsch, P., Stayte, S., & Vissel, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1682979 · Cited by 3
Metadata
- Authors
- Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K.
- Venue
- Experimental & Molecular Medicine
- Published
- 2016-01-22
- Volume
- 48
- Issue
- 1
- Pages
- e205-e205
- ISSN
- 2092-6413
- Cited by
- 119
- References
- 15
- Language
- en
- Licence
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.